Peptides DB
Research-centric peptide and protocol reference hub
Study 4 of 10Zenagamtide literaturePediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · Observational2023

Haemophilus abundance is associated with response to sublingual immunotherapy in children with allergic rhinitis.

Elevated nasal Haemophilus levels are linked to more severe allergic rhinitis in children, and its reduction after treatment may indicate a positive response to sublingual immunotherapy.

Read at Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and ImmunologyAdd to compare

Where it sits

this study against the rest of the zenagamtide corpus
2
Preclinical
4
Observational · this one
0
Open-label
3
Randomised
1
Reviews

Summary and findings

This study evaluated the relationship between Haemophilus abundance and response to sublingual immunotherapy (SLIT) in children with allergic rhinitis (AR). A total of 63 children with AR and 40 healthy controls were enrolled, with patients stratified by disease severity. Results indicated that elevated nasal Haemophilus is associated with AR severity and its depletion correlates with SLIT efficacy.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
LDA score >4, p<0.001 for Proteobacteria abundance in MSAR patients.n=632023

Abstract

The authors’ words, as Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology supplied them

<h4>Background</h4>The nasal microbiome's role in predicting sublingual immunotherapy (SLIT) efficacy in children with allergic rhinitis (AR) remains unclear. Haemophilus, a Proteobacteria genus linked to respiratory inflammation, is a promising candidate biomarker.<h4>Objective</h4>To evaluate Haemophilus dynamics as a potential predictor of SLIT response in children with moderate-severe AR.<h4>Methods</h4>In this prospective cohort, 63 children with AR and 40 healthy controls (CG) were enrolled. AR patients were stratified by disease severity (mild [MAR] vs. moderate-severe [MSAR]), with MSAR patients receiving 1-year standardized house dust mite SLIT. Based on >20% reduction in Total Nasal Symptom Score (TNSS), patients were classified as responders (RG, n = 25) or non-responders (NRG, n = 15). Nasal microbiome was profiled via 16S rDNA sequencing.<h4>Results</h4>Compared to CG, AR children showed increased alpha diversity (Chao1, p < .05; Shannon, p < .01) and enrichment of Staphylococcus. MSAR patients had significantly higher Proteobacteria abundance, particularly Haemophilus, compared to MAR (LDA score >4, p < .001). After SLIT, RG patients showed normalized microbial evenness (Pielou E index) to CG levels, driven by marked Haemophilus depletion (p < .001). In contrast, NRG patients maintained high Haemophilus abundance. Haemophilus and Moraxella showed strong positive correlation (r = .68, p < .001), with both decreasing in RG post-SLIT.<h4>Conclusion</h4>Elevated nasal Haemophilus is associated with AR severity, and its depletion correlates with SLIT efficacy. Haemophilus may serve as a clinically actionable microbial biomarker for monitoring SLIT response in pediatric AR, offering a novel precision medicine approach to allergen immunotherapy.

Background

The role of the nasal microbiome in predicting the efficacy of sublingual immunotherapy (SLIT) in children with allergic rhinitis (AR) is not well understood. Previous research has suggested that specific microbial profiles may influence respiratory inflammation and treatment outcomes. This study aims to clarify the association between Haemophilus dynamics and SLIT response, potentially identifying a biomarker for monitoring treatment efficacy in pediatric AR.

Methods

This prospective cohort study included 63 children with AR and 40 healthy controls. AR patients were stratified by disease severity into mild (MAR) and moderate-severe (MSAR) groups, with MSAR patients receiving 1-year standardized house dust mite SLIT. Patients were classified as responders or non-responders based on a >20% reduction in Total Nasal Symptom Score (TNSS). The nasal microbiome was profiled using 16S rDNA sequencing.

Results

Compared to healthy controls, AR children exhibited increased alpha diversity (Chao1, p<0.05; Shannon, p<0.01) and higher levels of Staphylococcus. MSAR patients had significantly greater Proteobacteria abundance than MAR patients (LDA score >4, p<0.001). Following SLIT, responders showed normalized microbial evenness (Pielou E index) to levels comparable to healthy controls, driven by significant Haemophilus depletion (p<0.001), while non-responders retained high Haemophilus levels.

Interpretation

The findings suggest that elevated Haemophilus levels are associated with increased severity of AR and that its depletion may indicate a positive response to SLIT. However, the clinical significance of these findings should be interpreted with caution, as the effect sizes may not be substantial enough to warrant changes in practice without further validation. Limitations such as small sample size and the observational nature of the study may confound the conclusions drawn.

Key findings

  • Increased alpha diversity in AR children compared to controls (Chao1, p<0.05; Shannon, p<0.01).
  • MSAR patients had significantly higher Proteobacteria abundance compared to MAR (LDA score >4, p<0.001).
  • RG patients showed marked Haemophilus depletion post-SLIT (p<0.001).
  • NRG patients maintained high Haemophilus abundance.
  • Strong positive correlation between Haemophilus and Moraxella (r=0.68, p<0.001).

Limitations

  • small sample size of 63 AR children
  • observational cohort design
  • short follow-up duration
  • no long-term outcome data

Elsewhere in the Zenagamtide corpus

DEfficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial.Lancet (London, England) · 2026DEfficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial.Lancet (London, England) · 2026DTranscriptomic and Metabolomic Analysis Reveals the Molecular Mechanisms of the Impact on the Fruiting Body Phenotype of &lt;i&gt;Lentinula edodes&lt;/i&gt; Under Different Light Conditions.Journal of fungi (Basel, Switzerland) · 2026 · 228.12 g productivity per log under blue light.AEffects of remimazolam vs. propofol on plasma neurofilament light chain and postoperative delirium in frail elderly patients undergoing major non-cardiac surgery: a prospective, randomized, assessor-blinded controlled trial.BMC anesthesiology · 2026 · n=123 · Plasma NfL concentrations on postoperative day 1 were 123.3[83.6-198.2] pg/ml for Group R and 149.0[102.0-226.6] pg/ml for Group P, P=0.186.HumanDEnvironmental classification of synthetic methods for zinc oxide nanoparticles: a comparative review of sustainable green and conventional approaches with their diverse applications.Nanoscale advances · 2026reviewBRenal Impairment Does Not Affect Pharmacokinetics, Safety or Tolerability of Zenagamtide.Diabetes, obesity & metabolism · 2026 · n=42 · AUC0-∞ ranged from 520-715 h × nmol/L across renal impairment groups versus 543 h × nmol/L for normal renal function group.Human